

To,

Date: 11.08.2021

1. BSE Limited P.J.Towers, Dalal Street Mumbai - 400001	2. Metropolitan Stock Exchange of India Limited, Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai - 400098
---	--

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 11.08.2021

Ref: Scrip Code 539267, DRHABEEB

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Wednesday, 11.08.2021 at 3:30 p.m. at 6-3-354/13/B2, Flat.No.B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500034, Telangana, the following were considered and approved:

1. Un-Audited financial results (standalone and consolidated) for the quarter ended 30.06.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2021. **(Enclosed)**
3. Change of Registered Office from Sy. No. 36, Chintalmet X Roads, Upparapally, Attapur, Rajendra Nagar Mandal, Hyderabad-500048, Telangana to 6-3-354/13/B2, Flat.No.B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500034, Telangana w.e.f. 11.08.2021.
4. Change of Corporate Office from No. 11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008, Telangana to 6-3-354/13/B2, Flat.No.B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500034, Telangana w.e.f. 11.08.2021.
5. Notice of 25<sup>th</sup> Annual General Meeting of the Members of the Company to be held on Wednesday 15<sup>th</sup> of September, 2021 at 9:00 a.m. through video conferencing/other audio visual means.


The meeting concluded at 5:30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,

For Dr Habeebullah Life Sciences Limited

K. Krishnam Raju  
Chairman & Whole-time Director

DIN: 00874650

Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)


Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upparapally, Rajendra Nagar Mandal, Hyderabad-500048. TS.  
India.Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-  
500008. TS. India.CIN No.: L85110TG1996PLC099198. Email: [cs@drhsl.com](mailto:cs@drhsl.com), [info@drhsl.com](mailto:info@drhsl.com),  
[pcproductsindia@gmail.com](mailto:pcproductsindia@gmail.com) Contact No.: 040 - 2970 3333, +91 9030057370. Website : [www.drhsl.com](http://www.drhsl.com)

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2021**

(INR In Lakhs)

Particulars	STANDALONE FINANCIALS			
	Quarter Ended			
	3 Months Ended 30/6/2021	Preceding 3 Months Ended 31/03/2021	Corresponding 3 months ended in previous year 30/06/2020	Previous Year Ended 31-03-2021
	UnAudited	Audited	UnAudited	Audited
<b>I</b> Revenue from Operations	-	-	1.30	1.30
<b>II</b> Other Income	3.95	3.85	3.54	14.77
<b>III</b> Total Revenue (I+II)	<b>3.95</b>	<b>3.85</b>	<b>4.84</b>	<b>16.07</b>
<b>IV</b> Expenses				
Cost of Material Consumed	-	-	0.19	0.19
Employee benefits expense	0.66	0.78	12.24	33.17
Depreciation and Amortisation expense	0.13	0.17	0.26	0.96
Other Expenses	7.57	5.01	18.48	58.72
<b>Total Expenses</b>	<b>8.36</b>	<b>5.96</b>	<b>31.17</b>	<b>93.04</b>
<b>V</b> Profit/(Loss) from before Exceptional Items and tax (I-IV)	<b>(4.41)</b>	<b>(2.11)</b>	<b>(26.33)</b>	<b>(76.97)</b>
<b>VI</b> Exceptional Items	-	-	-	-
<b>VII</b> Profit/(Loss) before tax (V-VI)	<b>(4.41)</b>	<b>(2.11)</b>	<b>(26.33)</b>	<b>(76.97)</b>
<b>VIII</b> Tax Expense:				
Current Tax	-	-	-	-
Deferred Tax	-	-	-	-
<b>IX</b> Profit/ (Loss) for the period from Continuing operations (VII-VIII)	<b>(4.41)</b>	<b>(2.11)</b>	<b>(26.33)</b>	<b>(76.97)</b>
<b>X</b> Profit/ (Loss) from discontinuing operations	-	-	-	-
<b>XI</b> Tax Expense of discontinuing operations	-	-	-	-
<b>XII</b> Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)				
<b>XIII</b> Profit/ (Loss) for the period (IX+XII)	<b>(4.41)</b>	<b>(2.11)</b>	<b>(26.33)</b>	<b>(76.97)</b>
<b>XIV</b> Other Comprehensive Income				
A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss				
(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss		12.67		14.08
<b>XV</b> Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	<b>(4.41)</b>	<b>10.56</b>	<b>(26.33)</b>	<b>(62.89)</b>
<b>XVI</b> Comprehensive Income attributable to Non Controlling Interest	-	-	-	-
<b>XVII</b> Comprehensive Income attributable to Owners of the company	<b>(4.41)</b>	<b>10.56</b>	<b>(26.33)</b>	<b>(62.89)</b>
<b>XVIII</b> Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
1) Basic	(0.03)	0.07	(0.18)	(0.42)
2) Diluted	(0.03)	0.07	(0.18)	(0.42)
<b>XIX</b> Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)				
1) Basic	-	-	-	-
2) Diluted	-	-	-	-
<b>XX</b> Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
1) Basic	(0.03)	0.07	(0.18)	(0.42)
2) Diluted	(0.03)	0.07	(0.18)	(0.42)
<b>XXI</b> Paid Up Equity Share Capital (Face Value of INR 10/- per share)	<b>1,480.87</b>	<b>1,480.87</b>	<b>1,480.87</b>	<b>1,480.87</b>

72



**Notes:**

1. The above unaudited standalone financial results for the quarter ended 30 June 2021 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Wednesday 11th August 2021.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
4. The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K Krishnam Raju  
Executive Chairman (DIN 00874650)




Place : Hyderabad  
Date: 11/08/2021

**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2021**

(INR In Lakh)

Particulars	CONSOLIDATED FINANCIALS			
	Quarter Ended			
	3 Months Ended 30-06-2021	Preceding 3 months ended 31-03-2021	Corresponding 3 months ended in previous year 30-06-2020	Previous Year Ended 03-2021
	Audited	Audited	Audited	Audited
I Revenue from Operations	-	-	1.30	1.30
II Other Income	3.95	3.85	3.54	14.77
III Total Revenue (I+II)	3.95	3.85	4.84	16.07
IV Expenses				
Cost of Material Consumed	-	-	0.19	0.19
Employee benefits expense	0.66	0.78	12.84	34.97
Depreciation and Amortisation expense	0.13	0.21	0.33	1.21
Other Expenses	7.57	5.90	18.63	59.86
Total Expenses	8.36	6.89	31.99	96.23
V Profit/(Loss) from before Exceptional Items and tax (I-IV)	(4.41)	(3.04)	(27.15)	(80.16)
VI Exceptional Items	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	(4.41)	(3.04)	(27.15)	(80.16)
VIII Tax Expense:				
Current Tax	-	-	-	-
Deferred Tax	-	(2.49)	-	(2.49)
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(4.41)	(0.55)	(27.15)	(77.67)
X Profit/ (Loss) from discontinuing operations	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	(4.41)	(0.55)	(27.15)	(77.67)
XIV Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss				
		14.08		14.08
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(4.41)	13.53	(27.15)	(63.58)
XVI Comprehensive Income attributable to Non Controlling Interest	-	-	-	(0.33)
XVII Comprehensive Income attributable to Owners of the company	(4.41)	13.53	(27.15)	(63.24)
XVIII Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
1) Basic	(0.03)	0.09	(0.19)	(0.43)
2) Diluted	(0.03)	0.09	(0.19)	(0.43)
XIX Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted				
XX Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
1) Basic	(0.03)	0.09	(0.19)	(0.43)
2) Diluted	(0.03)	0.09	(0.19)	(0.43)
XXI Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,480.87

*Handwritten signature*




**Notes:**

1. The above unaudited Consolidated financial results for the quarter ended 30 June 2021 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Wednesday 11th August 2021.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
4. The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K Krishnam Raju  
Executive Chairman(DIN 00874650)



Place : Hyderabad  
Date: 11/08/2021




# A.M. REDDY & D.R. REDDY

## CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Standalone unaudited Quarterly Financial results of Dr Habeebullah Life Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


To,  
The Board of Directors,  
Dr Habeebullah Life Sciences Limited.


1. We have reviewed the accompanying statement of standalone unaudited financial results of Dr Habeebullah Life Sciences Limited ("the Company") for the quarter ended June 30, 2021 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.



4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in india has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A M Reddy & D R Reddy  
Chartered Accountants  
FRN:0090685

  
D.Rama Krishna Reddy  
Partner  
M.No.209211



Place : Hyderabad  
Date: 11/08/2021

UDIN : 21209211AAAACD8318




# A.M. REDDY & D.R. REDDY

## CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Consolidated unaudited Quarterly Financial results of Dr Habeebullah Life Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
The Board of Directors,  
Dr Habeebullah Life Sciences Limited.

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Dr Habeebullah Life Sciences Limited ("the Holding Company"), its subsidiary, (the Holding company and its subsidiary together referred as the "group") for the quarter ended June30,2021("the Statement ") attached herewith, being submitted by the Holding company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the Holding company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we donot express an audit Opinion.





4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (listing obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement Includes the results of the Following Entities :

SN	Name of the Company	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

5. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in india has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Consolidated unaudited financial results include the interim financial information of the subsidiary, (mentioned in paragraph 3 above) which have not been reviewed or audited by their auditors, whose interim financial information reflect total revenue (before consolidation adjustments) of Nil and Total Loss after Tax (before Consolidated adjustments) of Rs.4.41 Lakhs for the quarter ended June 30,2021 respectively, as considered in the Statement. According to the information and Explanations given to us by the management, this interim financial information is not material to the Group

For A M Reddy & D R Reddy


Chartered Accountants

FRN/0090685

D.Rama Krishna Reddy

Partner

M.No.209211



Place : Hyderabad

Date: 11/08/2021

UDIN : 21209211AAAACC9421